The war with Iran has disrupted the Strait of Hormuz — one of the world’s busiest shipping lanes — putting the global pharmaceutical supply chain at risk.
Why it matters
– The U.S. gets nearly half of its generic prescriptions from India. Many Indian drugmakers route shipments through the Strait of Hormuz and also import oil and petrochemical feedstocks (solvents, coatings, packaging, plastics, IV bags, syringes) that are essential to drug manufacture.
– Attacks and blockades have closed or slowed traffic and damaged petrochemical facilities. Even if shipping resumes, logistics experts say cleared backlogs take significantly longer than the pause itself: about 1.5 weeks to clear one week of halted traffic. That means delays can cascade for months.
What’s already been seen
– India’s exports fell sharply: a roughly 25% drop in March, according to the reporting cited by medical experts.
– Damage to petrochemical production and interrupted oil flows can constrain raw materials and drive up costs for drug makers and manufacturers of packaging and medical supplies.
Dr. Celine Gounder’s assessment (paraphrased)
– Shortages have not fully materialized yet, but experts expect some in a few months if disruptions continue.
– Two main groups of medicines are most vulnerable: (1) high-volume generics made in large batches and shipped by sea, and (2) temperature-sensitive products usually flown through regional air hubs that have been affected by closures.
Medications most at risk
– High-volume generics: common, widely used off-patent drugs such as many blood‑pressure medications, statins for cholesterol, metformin for diabetes, and frequently prescribed antibiotics (for example, amoxicillin).
– Temperature‑sensitive medicines: insulin, certain cancer chemotherapies, and some vaccines, which rely on air freight and cold‑chain handling through hubs like Dubai, Abu Dhabi and Doha; airport shutdowns and re-routing slow supply and raise costs.
– Medical supplies: shortages or higher prices for plastics, IV bags, syringes and components can affect delivery and production.
Other impacts
– Helium supply: Qatar’s Ras Laffan liquefied‑natural‑gas facility — a source of helium used to cool MRI machines — was attacked; that event, plus transport issues via the Strait of Hormuz, threaten helium availability and could affect MRI access and operating costs.
– Clinical trials: trials conducted overseas can be delayed by transport and regulatory/logistical issues, slowing new drug development or trial continuity.
Practical advice
– Pharmacies typically keep 30–60 days’ supply on hand. If you rely on regular medications, check that your prescription is current and refill earlier than usual where possible.
– Talk with your clinician or pharmacist about alternatives only under medical guidance — do not switch or stop medications without professional advice.
Bottom line
No widespread shortages have been declared yet, but supply risks are rising because of disrupted shipping, damaged petrochemical capacity and strained air routes. Continued monitoring, early refills and coordination with healthcare providers can reduce short‑term patient risk while manufacturers and logistics firms adjust.